
    
      The study is a multicenter, randomized, double-blind, placebo-controlled, 12-week trial. To
      determine whether oral simiaowan at standard clinical doses (6g twice daily), compared to
      placebo, can reduce the incidence of acute gout flares and decrease the serum uric acid
      level.
    
  